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Abstract
Obstructive sleep apnoea (OSA) is a cardio-metabolic disorder. Whether metabolic syndrome
(MS), insulin resistance (IR) and albuminuria are independently associated with OSA is unclear, but
defining the interactions between OSA and various cardiovascular (CV) risk factors independent of
obesity facilitates the development of therapeutic strategies to mitigate their increased CV risks.
We prospectively recruited 38 subjects with OSA and 41 controls. Anthropometric
measurements, glucose, lipids, insulin and blood pressure (BP) were measured after an overnight
fast. IR state was defined as homeostasis model assessment (HOMA) value >3.99 and MS diagnosed
according to the International Diabetes Federation (IDF) criteria. Subjects with OSA were more
obese, more insulin resistant, more hyperglycaemic, had higher Epworth score (measure of day
time somnolence) and systolic blood pressure levels. The prevalence of MS was higher in OSA
compared with non-OSA subjects (74% vs 24%, p < 0.001). The prevalence of microalbuminuria in
both groups was negligible. Logistic regression adjusted for age, BMI and smoking showed that the
patient with OSA was 5.9 (95% CI 2.0–17.6) times more likely to have MS than non-OSA patient.
Triglyceride (p = 0.031), glucose (0.023) and Epworth score (0.003) values were independently
associated with OSA after adjusting for BMI and other covariates whilst IR status was found not to
be significant. Using the ROC curve analysis, we found that a waist circumference of >103 cm would
predict MS in patients with OSA at 75–78% sensitivity and 61–64% specificity. The agreement
between MS and IR state in this cohort is poor. Thus, OSA is associated with MS independent of
obesity predominantly due to increased triglyceride, glucose and Epworth score values but not IR
or microalbuminuria status. This observation suggests an alternative pathogenic factor mediating
the increased cardiovascular risk in patients with OSA and MS, other than that due to IR. The
independent link between Epworth score and MS in patients with OSA implicates the role of
daytime sleepiness and chronic hypoxia as a potential mediator. Given the discordant between MS
and IR state, measurement of waist is useful for predicting mainly MS but not insulin resistance
status in patients with OSA. Appropriate pharmacological intervention targeting these independent
factors is important in reducing the increased CV risks among patients with OSA.
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Background
Obstructive Sleep Apnoea (OSA) has been linked with
increased cardiovascular disease (CVD) [1,2]. While obes-
ity per se was previously thought to confer independent
vascular risk, more recent studies have provided strong
evidence that OSA itself is associated with hypertension
[3], dyslipidaemia [4] and impaired glucose tolerance [5],
independent of obesity. These proatherogenic factors
when clustered together in the same individual are known
as the Metabolic Syndrome [6].
Insulin resistance has been implicated as central to the
pathogenicity of the Metabolic Syndrome [6]. Because
central obesity is strongly associated with insulin resist-
ance and generalised endothelial dysfunction [7], waist
circumference has been adopted as a surrogate for an indi-
vidual's insulin resistance status and risk of CVD. Studies
on the relationship between insulin resistance and OSA
however have yielded conflicting results, with some stud-
ies showing significant associations between the two [8,9]
while others have not [10,11]. Similarly, studies looking
at the effect of treatment of OSA on insulin resistance have
also produced contradictory reports, e.g. continuous pos-
itive airway pressure (CPAP) treatment improves insulin
resistance in one [12] but not in another study [13]. There
is also considerable doubt whether subgroup of patients
with metabolic syndrome are indeed insulin resistant
[14]. In addition, neck circumference rather than waist cir-
cumference has been previously reported to be the most
important predictor of OSA amongst all anthropometric
variables studied [11]. Thus, the associations between the
metabolic syndrome, insulin resistance state and central
obesity may not necessarily apply among patients with
OSA. It also remains unclear if microalbuminuria, a
marker of generalised endothelial dysfunction is more
prevalent among patients with OSA. Increased under-
standing on the independent associations between OSA,
metabolic syndrome, insulin resistance and microalbu-
minuria status is important in order to develop appropri-
ate therapeutic strategies to reduce the high
cardiometabolic risks in patients with OSA.
The purpose of this study was therefore to: (i) investigate
the independent associations between OSA, metabolic
syndrome and insulin resistance, (ii) determine if waist
and neck circumference could be used to predict the pres-
ence of metabolic syndrome and insulin resistance among
patients with OSA and (iii) assess the prevalence of micro-
albuminuria in patients with OSA.
Methods
Subjects and measurements
Consecutive subjects referred to the sleep laboratory at the
Sherwood Forest Hospitals NHS Trust for suspected sleep
apnoea were recruited. Subjects who were taking glucose
lowering agents, lipid lowering treatment or those with
evidence of significant renal, liver and cardiac disease
were excluded. Because of the many diagnostic criteria
available for metabolic syndrome, power calculation was
derived from systolic and diastolic blood pressure values
(a universal component for all metabolic syndrome crite-
ria) previously reported for OSA patients. A sample size of
32 patients per group are required to detect a 10-mmHg
difference in systolic blood pressure and a 5-mmHg differ-
ence in diastolic blood pressure with a power of 80% (β
error = 0.2), α = 0.0510. A total of 79 patients were
included in the study (38 patients with newly diagnosed
OSA and 41 subjects with no OSA). All subjects under-
went an in-patient sleep study assessment. A question-
naire on demographics, medical history, medications,
lifestyle and physical activity was completed prior to their
study. Daytime sleepiness was assessed using the Epworth
sleepiness score. Body habitus was measured in light
clothing using standard athropometric methods. Waist
circumference was measured midway between the lower
costal margin and the iliac crest and neck circumference at
the level of the laryngeal prominence. Blood pressure was
taken in the sitting position using Dinamap (Critikon Inc,
Florida) after 5 minutes of rest. Venous blood was
obtained in the fasting state on the morning after the sleep
study for the measurement of glucose, insulin, lipids and
other routine biochemistry. Mid stream urine (MSU) was
analysed for the presence of microalbuminuria using the
albumin-creatinine ratio. All subjects gave written
informed consent to the study. The study was approved by
the local research ethics committee.
Sleep study assessment
All patients underwent a standard sleep study, using the
minimal patient contact sleep diagnosis system (VISI-3,
Stowood Scientific Instruments Ltd (SSI), Oxford), which
included the following parameters: digital Video/audio,
calibrated sound level measurement, electrocardiography,
R-R timing, pulse transit time, airflow, respiratory effort,
body position and movement. Oxyhaemoglobin satura-
tion (SaO2) was measured by a pulse oxymetry. A software
package was used for downloading, viewing, reporting
and analysis of trend recording oximeters and capnome-
ters. Continuous nasal airflow delivery was by Horizon
Nasal CPAP system.Cardiovascular Diabetology 2006, 5:22 http://www.cardiab.com/content/5/1/22
Page 3 of 7
(page number not for citation purposes)
Insulin resistance and metabolic syndrome assessment
We used homoestasis model assessment (HOMA-IR
index) as a measure of insulin sensitivity [plasma glucose
(mol/l) × plasma insulin (mU/l)/22.5] – an established
test in epidemiological studies. We defined insulin resist-
ance as a HOMA score >3.99, on the basis of a definition
for a white population [15]. The Metabolic Syndrome is
diagnosed according to the recent IDF guidelines [16], i.e.
central obesity, defined as waist equal to or more than 94
cm for males and 80 cm for females; plus two of the fol-
lowing: triglycerides >1.7 mmol/L; HDL-cholesterol
<1.04 mmol/L in males and <1.29 mmol/L in females;
blood pressure >130/85 mm Hg or use of antihyperten-
sive agent; and fasting hyperglycemia, defined as glucose
= or >5.6 mmol/L or previous diagnosis of diabetes or
impaired glucose tolerance.
Statistical analysis
Normally distributed data were presented as means ±
standard error mean (SEM), skewed data as the median
(ranges) and categorical data as percentage. In this cohort
of patients who are significantly obese, gender differences
in weight, waist, blood pressure and BMI are negligible.
Analysis for both males and females were therefore per-
formed together where appropriate. Univariate compari-
son of clinical parameters between OSA and non OSA
subjects were made using the unpaired t-test or Mann-
Whitney test and categorical variables were compared
using the Chi-square test. To determine whether OSA is
associated with insulin resistance state, metabolic syn-
drome and individual CVD risk factors independent of
obesity, a univariate and multivariate regression analysis
(adjusted for age, BMI and smoking history) was per-
formed. Where we had the dependent variable being cate-
gorical we used the logistic regression technique. Fasting
insulin, HOMA, fasting triglyceride and HDL values were
logarithmically transformed before they were used as
dependent variables to satisfy the normality requirement.
A kappa test (κ-test) was used to assess the agreement
between metabolic syndrome and insulin resistance status
for individual patients within the cohort. A receiver oper-
ating characteristics (ROC) curve was used to select an
appropriate cut-off for waist, neck circumferences and
Epworth score values that would independently predict
likelihood of insulin resistance state and metabolic syn-
drome status among patients with and without OSA.
Results
The demographics of our study group are summarised in
table 1. In this unadjusted analysis, subjects with OSA had
a greater BMI, waist circumference, systolic blood pres-
sure, fasting glucose, fasting triglyceride, fasting insulin,
HOMA and Epworth score levels compared with non OSA
subjects. The prevalence of the metabolic syndrome was
significantly higher in the OSA group compared with non
OSA subjects, (73% v 37%, p < 0.001). Other metabolic
characteristics included were not significantly different
between the two groups. The prevalence of microalbu-
minuria in both groups was negligible.
Table 2 summarises independent associations between
various demographic and biochemical profiles with the
metabolic syndrome and insulin resistance status. After
adjustment for age, BMI and smoking history, followed by
stepwise multiple regression analysis, only fasting glu-
cose, fasting triglyceride and Epworth score levels were
independently associated with a diagnosis of OSA. Based
on this analysis, we found that the presence of OSA was
independently associated with a nearly six-fold increased
risk of having the metabolic syndrome, (OR = 5.88, 95%
CI 1.96–17.63, p = 0.002). No independent association
was found between OSA and insulin resistance state (OR
= 0.54, 95% CI 0.54–1.64, p = 0.3) (Table 3). Because
waist circumference is strongly correlated with BMI (r =
0.86), the independent association between OSA and
metabolic syndrome persists when adjusted for waist cir-
cumference (p = 0.002). Using κ-test, we found that the
agreement between subjects' insulin resistance state and
the metabolic syndrome status for the study cohort was
poor (κ = 0.31, 95% CI 0.09–0.52).
On the basis of the ROC curves analysis, we found that an
optimal waist circumference cut-off for detecting meta-
bolic syndrome to be at 103 cm. Sensitivities and specifi-
cities for this cut off level were between 75–78% and 61–
64% respectively. For neck circumference, an optimal cut
off of 42 cm was set for men, with sensitivities and specif-
icities of 78% and 60% respectively. No suitable neck cir-
cumference cut off was found for women (Figure 1).
Using similar analysis, we set the optimal cut-off for
detecting insulin resistance state at 105 cm for waist cir-
cumference in both sexes (sensitivity and specificity of
78% and 62% respectively). No suitable neck circumfer-
ence cut off value could be used for detecting the presence
of insulin resistance state. Similarly, Epworth score criteria
could not be used to detect the presence of metabolic syn-
drome or insulin resistance state in this cohort.
Discussion
In this hospital based cohort, OSA was shown to be inde-
pendently associated with the metabolic syndrome (IDF
criteria), driven largely by increased serum triglyceride,
elevated glucose and day-time sleepiness but not with
insulin resistance state. The agreement between subjects'
metabolic syndrome and insulin resistance status is poor.
These findings suggest that in patients with OSA, other
mechanisms other than insulin resistance may play a big-
ger role in the pathophysiology of the metabolic syn-
drome. Waist circumference could be used to help identify
patients with metabolic syndrome, whereas neck circum-Cardiovascular Diabetology 2006, 5:22 http://www.cardiab.com/content/5/1/22
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Table 1: Comparison of clinical and biochemical characteristics in patients with or without obstructive sleep apnoea
non OSA (n = 41) OSA (n = 38) p
Age (years) 47.3 ± 1.7 51.0 ± 2.0 0.17
BMI (kg/m2) 30.9 ± 1.1 35.8 ± 1.5 0.01
Waist (cm) 102.1 ± 2.4 114.4 ± 3.0 0.02
Neck (cm) 40.7 ± 0.7 42.7 ± 1.1 0.12
S m o k i n g  ( % ) 1 7 . 72 9 . 70 . 1 2
Epsworth score 9.51 ± 0.7 13.7 ± 0.9 <0.001
Systolic BP (mmHg) 134.2 ± 2.8 147.1 ± 3.8 0.009
Diastolic BP (mmHg) 82.0 ± 1.7 82.8 ± 2.3 0.784
Total cholesterol (mmol/l) 5.3 ± 0.2 5.2 ± 0.2 0.770
LDL-cholesterol (mmol/l) 3.2 ± 0.2 3.0 ± 0.2 0.308
HDL-cholesterol (mmol/L) 1.3 ± 0.05 1.2± 0.05 0.118
Triglyceride (mmol/l) 1.7 ± 0.2 2.3 ± 0.2 0.010
Glucose (mmol/L) 5.1 ± 0.1 5.9 ± 0.3 0.005
Insulin (pmol/L) 13.7 ± 2.0 21.5 ± 3.3 0.049
HOMA IR 3.1 ± 0.4 6.4 ± 1.3 0.019
Microalbuminuria (%) 6.7 10.8 N/A
Metabolic syndrome (%) 37 73 <0.001
Table 2: Multiple regression analysis looking at the independent associations between obstructive sleep apnoea with cardiovascular and 
anthropometric parameters after adjustment for age, BMI and smoking history. t and p values corresponds to OSA v non OSA status.
VARIABLES t-value p-value
Systolic blood pressure -1.83 0.071
Diastolic blood pressure 0.34 0.737
Waist -0.85 0.398
Neck -0.46 0.646
Total cholesterol 0.09 0.931
LDL cholesterol 0.66 0.511
HDL cholesterol* 0.97 0.337
Triglyceride* -2.19 0.031
Glucose -2.32 0.023
Insulin* -0.71 0.482
Epworth score -3.05 0.003
* log transformed prior to analysis
Table 3: Independent associations between obstructive sleep apnoea and metabolic syndrome or insulin resistance status (after 
adjustments for age, BMI, smoking history)
Parameters P Odds ratio (confidence interval)
Metabolic syndrome 0.002 5.88 (95% CI 1.961–17.63)
Insulin resistance 0.279 0.54 (95% CI 0.544–1.642)Cardiovascular Diabetology 2006, 5:22 http://www.cardiab.com/content/5/1/22
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ROC curve analysis to determine cut off values for waist and neck circumference that would predict (a) metabolic syndrome  and (b) insulin resistance Figure 1
ROC curve analysis to determine cut off values for waist and neck circumference that would predict (a) metabolic syndrome 
and (b) insulin resistance.
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ferences showed no appropriate cut off values. Our obser-
vations enhance findings of previous studies and expand
knowledge of the clinical utility of measuring waist cir-
cumference for detecting metabolic syndrome and insulin
resistance. The study have also provided important infor-
mation regarding appropriate targets for therapeutic inter-
vention among patients with OSA in order to reduce their
cardio-metabolic risks.
Insulin resistance is generally believed to play a central
role in the clustering phenomenon of CVD risk factors
that defines the metabolic syndrome [6]. The relationship
between insulin resistance and OSA however is somewhat
unclear [8-13]. Discrepancies in study outcomes may be
explained by differences in study population or method-
ologies but a more likely explanation is that the mechanis-
tic links between the various metabolic and biological
mechanism of increased CVD risks in patients with OSA is
one of complex interaction involving paradoxical rises in
blood pressure, cortisol levels and sympathetic activity
during sleep mediated by stress, hypoxia and increased
free fatty acid lipolysis [17,18]. The interpretation of in-
vivo  metabolic studies is further complicated because
hypoxia inhibits insulin secretion through decreased β-
cell ATP production [19] but may also reduce insulin
receptor tyrosine kinase activity leading to insulin resist-
ance and hyperinsulinaemia [20]. Although CPAP treat-
ment has been shown to improve HbA1c [21] and HDL-
cholesterol [22] levels in patients with OSA, the increas-
ingly reported associations between diabetes and sleep
disordered breathing, in terms of cause or effect [23,24],
has provided clinicians with a wider metabolic targets
potentially amenable to pharmacological and lifestyle
interventions. Observation from this study however does
not support the potential use of insulin sensitizer among
patients with OSA.
There is also evidence to suggest that OSA is independ-
ently associated with increased activation of the renin-
angiotensin-system [25] – an important correlate of cardi-
ovascular and metabolic risks. In support of this, a recent
study showed that abdominal adiposity is related to the
development of elevated albuminuria in both sexes [26].
Owing to the importance of microalbuminuria as a major
risk factor for CVD in the general population [26,27], the
World Health Organization (WHO) includes microalbu-
minuria in their criteria for diagnosing the metabolic syn-
drome [28]. Our study however showed that the
prevalence of microalbuminuria, a recognized marker of
systemic generalized endothelial dysfunction is negligible
in patients with OSA. After adjusting for known covariates
including BMI in our study, only raised triglyceride and
fasting glucose were independently associated with OSA.
These findings are important when considering pharma-
cological intervention for primary CVD prevention in
patients with OSA.
Because abdominal obesity is recognized to be a better
predictor of CVD than BMI [7,29], waist circumference
has been adopted to reflect individual's CVD risks. We
found that a waist circumference of >103 cm to be an
important predictor for metabolic syndrome state. This
cut point value concurs with findings from a study by
Laaka et al [30], who showed that CVD and overall mor-
tality was more consistently increased using a waist cir-
cumference criterion of 102 cm rather than the 94 cm
adopted by the IDF and the WHO to diagnose the meta-
bolic syndrome. While previous studies have shown that
neck circumference was the most important predictor of
OSA among all athropometric variables, observation from
our study did not support the use of neck circumference
for predicting metabolic syndrome or insulin resistance
status and concurs with finding from a more recent study
using nuclear magnetic resonance imaging (NMR) [31].
Several limitations of our study must be acknowledged.
This study was not designed to include matched control
subjects. Because the aims were to determine independent
associations between OSA, metabolic syndrome, insulin
resistance status and abdominal obesity, we included all
patients who fulfilled inclusion criteria to avoid selection
bias. There might also be confounding of metabolic and
haemodynamic parameters due to use of antihypertensive
drugs. This confounder is likely to be not significant
because the number of patients taking antihypertensive
drugs is small. Finally, although euglycaemic hyperinsuli-
naemic clamp is generally regarded as the gold standard
for measuring insulin sensitivity, HOMA-IR is a simpler,
inexpensive technique and has shown strong correlation
(r = 0.82) when validated against the insulin-clamp tech-
nique [32].
In conclusion, OSA is independently associated with the
metabolic syndrome but not insulin resistance state. The
observed independent association is largely driven by fast-
ing glucose and triglyceride levels. The agreement between
metabolic syndrome and insulin resistance status is poor
in this cohort, which concurs with studies from a more
general population cohort [33]. The biological mecha-
nism of increased CVD risk in patients with OSA is there-
fore likely to be multifactorial which includes the
parameters mentioned above and possibly hypoxia medi-
ated. Pharmacological interventions for patients with
OSA should therefore include strategies to lower serum
triglyceride, glucose in addition to lifestyle intervention
and CPAP therapy. Waist circumference measurement
could be a used to predicting metabolic syndrome and
possibly CVD risk in patients with OSA.Cardiovascular Diabetology 2006, 5:22 http://www.cardiab.com/content/5/1/22
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